Details of the Drug Combination

General Information of Drug Combination (ID: DC75JV6)

Drug Combination Name
Celecoxib Carboplatin
Indication
Disease Entry Status REF
Cancer Phase 1 [1]
Component Drugs Celecoxib   DM6LOQU Carboplatin   DMG281S
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL is unavailable

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Celecoxib
Disease Entry ICD 11 Status REF
Dysmenorrhea GA34.3 Approved [2]
Lung cancer 2C25.0 Approved [2]
Osteoarthritis FA00-FA05 Approved [2]
Rheumatoid arthritis FA20 Approved [3]
Pain MG30-MG3Z Phase 3 [3]
Colon cancer 2B90.Z Investigative [2]
Familial adenomatous polyposis 2B90.Y Investigative [2]
Precancerous condition N.A. Investigative [2]
Celecoxib Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Prostaglandin G/H synthase 2 (COX-2) TTVKILB PGH2_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------
Celecoxib Interacts with 5 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Metabolism [8]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Metabolism [9]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [10]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [11]
------------------------------------------------------------------------------------
Indication(s) of Carboplatin
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [4]
Carcinoma 2A00-2F9Z Approved [4]
Cholangiocarcinoma 2C12.10 Approved [4]
Cutaneous melanoma 2C30 Approved [4]
Epithelial ovarian cancer 2B5D Approved [4]
Fallopian tube neoplasm N.A. Approved [4]
Gastroesophageal junction adenocarcinoma 2B71 Approved [4]
Lung adenocarcinoma N.A. Approved [4]
Lung cancer 2C25.0 Approved [4]
Non-small-cell lung cancer 2C25.Y Approved [4]
Ovarian cancer 2C73 Approved [5]
Ovarian disorder N.A. Approved [4]
Ovarian neoplasm N.A. Approved [4]
Ovarian serous cystadenocarcinoma N.A. Approved [4]
Small-cell lung cancer 2C25.Y Approved [4]
Lung large cell carcinoma N.A. Investigative [4]
Neuroblastoma 2D11.2 Investigative [4]
Carboplatin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [12]
------------------------------------------------------------------------------------
Carboplatin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [13]
------------------------------------------------------------------------------------
Carboplatin Interacts with 7 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Metabolism [14]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Metabolism [14]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Metabolism [14]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Metabolism [14]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Metabolism [14]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Metabolism [14]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Metabolism [14]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DME(s)

References

1 ClinicalTrials.gov (NCT00581971) Radiosensitization With Celecoxib and Chemoradiation for Head and Neck Cancer
2 Celecoxib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2892).
4 Carboplatin FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7624).
6 Pfizer. Product Development Pipeline. March 31 2009.
7 Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000 May;293(2):453-9.
8 Sulfonation of 17beta-estradiol and inhibition of sulfotransferase activity by polychlorobiphenylols and celecoxib in channel catfish, Ictalurus punctatus. Aquat Toxicol. 2007 Mar 10;81(3):286-92.
9 Celecoxib is a substrate of CYP2D6: impact on celecoxib metabolism in individuals with CYP2C9*3 variants. Drug Metab Pharmacokinet. 2018 Oct;33(5):219-227.
10 Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics. 2009 Sep;10(9):1489-510.
11 Drug interactions in dentistry: the importance of knowing your CYPs. J Am Dent Assoc. 2004 Mar;135(3):298-311.
12 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
13 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
14 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)